Related Experiment Video

Updated: Feb 3, 2026

Isolation, Characterization, and Therapeutic Application of Extracellular Vesicles from Cultured Human Mesenchymal Stem Cells
07:03

Isolation, Characterization, and Therapeutic Application of Extracellular Vesicles from Cultured Human Mesenchymal Stem Cells

Published on: September 23, 2022

2.6K

Therapeutic use of mesenchymal stem cell-derived extracellular vesicles in acute lung injury

Jae Hoon Lee1,2, Jeonghyun Park1, Jae-Woo Lee1

  • 1Department of Anesthesiology, University of California at San Francisco, San Francisco, California.

Transfusion
|November 2, 2018
PubMed

Insights

Mesenchymal stem cell (MSC) extracellular vesicles (EVs) show promise for treating acute lung injury (ALI). These cell-free therapies may overcome safety and cost issues associated with MSCs, offering a potential alternative for respiratory failure.

Area of Science:

  • Regenerative Medicine
  • Pulmonary Medicine
  • Cell Biology

Background:

  • Acute respiratory distress syndrome (ARDS) is a critical cause of respiratory failure with high mortality and no effective pharmacotherapy.
  • Mesenchymal stem or stromal cells (MSCs) show therapeutic potential for acute lung injury (ALI) in preclinical models, with ongoing clinical trials.
  • Concerns regarding MSCs include tumor formation risk and high production/storage costs, limiting accessibility.

Purpose of the Study:

  • To review preclinical studies evaluating mesenchymal stem cell-derived extracellular vesicles (MSC EVs) as a treatment for ALI and other inflammatory lung diseases.
  • To explore MSC EVs as a potentially safer and more accessible alternative to MSC therapy for lung injury.
  • To identify challenges and requirements for the clinical translation of MSC EV therapy.

Main Methods:

  • Review of preclinical studies investigating the efficacy of MSC EVs in animal models of ALI and inflammatory lung conditions.
  • Analysis of the advantages of MSC EVs over MSCs and MSC-conditioned medium regarding safety, logistics, and therapeutic potential.
  • Examination of the requirements for large-scale production and standardization of MSC EVs for clinical application.

Main Results:

  • Preclinical studies suggest MSC EVs are a promising cell-free therapeutic approach for ALI.
  • MSC EVs may circumvent the safety concerns (e.g., tumorigenicity) and logistical hurdles associated with MSC transplantation.
  • MSC EVs retain the functional phenotype of parent MSCs, offering therapeutic benefits without direct cell administration.

Conclusions:

  • MSC EVs represent a compelling alternative to MSC therapy for acute lung injury and inflammatory lung diseases.
  • Further research and development are needed for large-scale production and standardization of MSC EVs for clinical use.
  • Standardization in identification, characterization, and quantification is crucial for the successful clinical translation of MSC EV therapeutics.

More Related Videos

Author Spotlight: Standardizing and Improving the Extraction and Purification of Extracellular Vesicles from Human ADSCs04:54

Author Spotlight: Standardizing and Improving the Extraction and Purification of Extracellular Vesicles from Human ADSCs

Published on: May 3, 2024

1.2K
A Simple Benchtop Filtration Method to Isolate Small Extracellular Vesicles from Human Mesenchymal Stem Cells09:10

A Simple Benchtop Filtration Method to Isolate Small Extracellular Vesicles from Human Mesenchymal Stem Cells

Published on: June 23, 2022

2.0K

Related Concept Videos

Mesenchymal Stem Cells01:19

Mesenchymal Stem Cells

Mesenchymal stem cells (MSCs) are adult stem cells that can differentiate into most connective tissue cell types, except for hematopoietic cells, depending upon the source of MSCs. For example, bone-marrow-derived MSCs (BM-MSCs) can differentiate into osteocytes, hepatocytes, and pancreatic and neuronal cells. MSCs can be isolated from various sources such as bone marrow, placenta, adipose tissue, teeth, and Wharton’s jelly, a gelatinous substance in the umbilical cord. The ease of their...
5.6K
Acute Kidney Injury I: Introduction01:22

Acute Kidney Injury I: Introduction

Introduction:Acute Kidney Injury (AKI) describes a swift decrease in kidney function occurring over hours to days, characterized by the kidneys' failure to remove waste products from the bloodstream. This leads to dangerous complications like metabolic acidosis, fluid overload, and electrolyte imbalances, such as hyperkalemia, which can cause life-threatening arrhythmias. AKI is common in both hospital and outpatient settings, often triggered by dehydration, sepsis, or exposure to nephrotoxic...
717
Acute Kidney Injury II: Pathophysiology01:29

Acute Kidney Injury II: Pathophysiology

Acute kidney injury (AKI) causes are categorized into three primary categories based on the location of the injury: prerenal, intrarenal (or intrinsic), and postrenal causes. This classification guides clinical management and illustrates how different pathways can impair kidney function.Etiology and Pathophysiology of Acute Kidney Injury1. Prerenal causesEtiology: Prerenal Acute Kidney Injury, the most common type, occurs when reduced blood flow to the kidneys decreases filtration capacity...
1.1K
Acute Kidney Injury VI: Nursing Management01:22

Acute Kidney Injury VI: Nursing Management

Acute Kidney Injury (AKI) results in an inability to maintain fluid, electrolyte, and acid-base balance. Effective nursing management is critical in improving patient outcomes and includes comprehensive patient assessment and targeted interventions.Comprehensive Patient AssessmentA detailed history collection is essential, focusing on any recent infections, nephrotoxic medication use, or chronic conditions such as hypertension and diabetes that may contribute to AKI. During the physical...
451
Acute Kidney Injury V: Interprofessional Care01:20

Acute Kidney Injury V: Interprofessional Care

Acute Kidney Injury (AKI) requires a collaborative healthcare approach to restore renal function and prevent complications. Essential management strategies involve monitoring fluid and electrolyte balance, adjusting medications, initiating dialysis when necessary, and providing nutritional support.Fluid and Electrolyte ManagementFluid Monitoring: Regularly monitoring body weight, central venous pressure, and urine output helps detect fluid imbalances early. Patient intake and output are...
355
Acute Kidney Injury III: Clinical Manifestations01:29

Acute Kidney Injury III: Clinical Manifestations

Acute Kidney Injury (AKI) progresses through distinct clinical phases: the oliguric, diuretic, and recovery phases, each marked by unique manifestations and challenges.Oliguric Phase:The oliguric phase is the initial stage of AKI, typically lasting 10 to 14 days. This phase is marked by a significant reduction in urine output, usually less than 400 mL per day, indicating decreased kidney function. Fluid retention is a prominent feature, leading to symptoms such as edema, hypertension, and...
932